Please try another search
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Name | Age | Since | Title |
---|---|---|---|
Una S. Ryan | 79 | 2013 | Independent Director |
Ramtin Agah | 55 | 2009 | Founder, Chairman of Board & Chief Medical Officer |
Kristen Angela Macfarlane | 56 | 2018 | Independent Director |
Laurence J. Marton | 80 | 2012 | Independent Director |
Karyn A. Goodman | - | 2017 | Member of Advisory Board |
Michael Pishvaian | - | 2017 | Member of Advisory Board |
Robert Jay Spiegel | 75 | 2023 | Independent Director |
Michel Ducreux | - | 2023 | Member of Scientific Advisory Board |
Margaret A. Tempero | - | 2023 | Member of Scientific Advisory Board |
Shaun R. Bagai | 47 | 2014 | CEO, Secretary & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review